FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2946931105> ?p ?o ?g. }

• W2946931105 endingPage "e027456" @default.
• W2946931105 startingPage "e027456" @default.
• W2946931105 abstract "To summarise real-world data from studies reporting golimumab persistence in European immune-mediated rheumatic disease (IMRD) populations and to report pooled estimates.Systematic literature review.Relevant literature was identified through searching Medline and Embase via Ovid as well as the conference databases of European League Against Rheumatism and American College of Rheumatology-Association of Rheumatology Health Professionals.We screened records using predefined patients, interventions, comparators, outcomes and study design criteria. Eligible studies included reports of persistence among adult IMRD patients in Europe receiving treatment with subcutaneous golimumab. Clinical trials, randomised controlled trials, literature reviews, editorials, guidelines and studies with <20 patients receiving golimumab were excluded.Following double screening by two independent reviewers, 27 studies out of 578 identified records were selected for inclusion and subsequent data extraction. Persistence was most commonly reported at 12and 24 months; hence, pooled persistence estimates were calculated for these two time points and reported according to indication.Persistence ranged between 58.1% (psoriatic arthritis (PsA) patients regardless of treatment line) and 75.7% (biological-naïve rheumatoid arthritis patients) at 12 months; at 24 months, the range was 43% (axial spondyloarthritis (AxSpA) patients regardless of treatment line) and 69.6% (biological-naïve PsA patients). On the basis of data from 12 studies, persistence with golimumab treatment was either significantly higher or not significantly different from other tumour necrosis factor inhibitors (TNFi).Golimumab persistence at 24 months approximates 50%, with a lower persistence among AxSpA (43%) patients. However, as the number of studies in these populations was low, they warrant further research. In 12 studies comparing various TNFi treatments, golimumab was shown to have significantly better or equal persistence to its comparators." @default.
• W2946931105 created "2019-06-07" @default.
• W2946931105 creator A5001993231 @default.
• W2946931105 creator A5018065406 @default.
• W2946931105 creator A5021326700 @default.
• W2946931105 creator A5031990860 @default.
• W2946931105 creator A5044492989 @default.
• W2946931105 creator A5046420010 @default.
• W2946931105 creator A5061609589 @default.
• W2946931105 creator A5068436236 @default.
• W2946931105 creator A5085444689 @default.
• W2946931105 date "2019-05-01" @default.
• W2946931105 modified "2023-10-13" @default.
• W2946931105 title "Real-world treatment persistence of golimumab in the management of immune-mediated rheumatic diseases in Europe: a systematic literature review" @default.
• W2946931105 cites W1482978402 @default.
• W2946931105 cites W1770652604 @default.
• W2946931105 cites W1969143953 @default.
• W2946931105 cites W1996927325 @default.
• W2946931105 cites W2045782334 @default.
• W2946931105 cites W2085122575 @default.
• W2946931105 cites W2092773063 @default.
• W2946931105 cites W2097973532 @default.
• W2946931105 cites W2106962952 @default.
• W2946931105 cites W2120393706 @default.
• W2946931105 cites W2128930739 @default.
• W2946931105 cites W2139062201 @default.
• W2946931105 cites W2140965629 @default.
• W2946931105 cites W2156098321 @default.
• W2946931105 cites W2158058290 @default.
• W2946931105 cites W2164421909 @default.
• W2946931105 cites W2166476511 @default.
• W2946931105 cites W2194197257 @default.
• W2946931105 cites W2216969607 @default.
• W2946931105 cites W2264156726 @default.
• W2946931105 cites W2265946565 @default.
• W2946931105 cites W2409325818 @default.
• W2946931105 cites W2412177641 @default.
• W2946931105 cites W2413330593 @default.
• W2946931105 cites W2417815581 @default.
• W2946931105 cites W246286872 @default.
• W2946931105 cites W2471354035 @default.
• W2946931105 cites W2523316498 @default.
• W2946931105 cites W2545396306 @default.
• W2946931105 cites W2551292120 @default.
• W2946931105 cites W2560815198 @default.
• W2946931105 cites W2571839963 @default.
• W2946931105 cites W2572897530 @default.
• W2946931105 cites W2604128221 @default.
• W2946931105 cites W2739400263 @default.
• W2946931105 cites W2754095800 @default.
• W2946931105 cites W2754573378 @default.
• W2946931105 cites W2755347709 @default.
• W2946931105 cites W2756405458 @default.
• W2946931105 cites W2762671932 @default.
• W2946931105 cites W2765444406 @default.
• W2946931105 cites W2792326343 @default.
• W2946931105 cites W2804124209 @default.
• W2946931105 cites W2807960509 @default.
• W2946931105 cites W2807963597 @default.
• W2946931105 cites W2808269532 @default.
• W2946931105 cites W2883546880 @default.
• W2946931105 cites W2888686038 @default.
• W2946931105 cites W2896199760 @default.
• W2946931105 cites W2899688403 @default.
• W2946931105 cites W2908801386 @default.
• W2946931105 cites W2908963576 @default.
• W2946931105 cites W2910509050 @default.
• W2946931105 cites W2910526070 @default.
• W2946931105 cites W2980703875 @default.
• W2946931105 cites W2982702367 @default.
• W2946931105 cites W4239319384 @default.
• W2946931105 cites W4294215472 @default.
• W2946931105 cites W2981237361 @default.
• W2946931105 doi "https://doi.org/10.1136/bmjopen-2018-027456" @default.
• W2946931105 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6549706" @default.
• W2946931105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31142529" @default.
• W2946931105 hasPublicationYear "2019" @default.
• W2946931105 type Work @default.
• W2946931105 sameAs 2946931105 @default.
• W2946931105 citedByCount "17" @default.
• W2946931105 countsByYear W29469311052020 @default.
• W2946931105 countsByYear W29469311052021 @default.
• W2946931105 countsByYear W29469311052022 @default.
• W2946931105 countsByYear W29469311052023 @default.
• W2946931105 crossrefType "journal-article" @default.
• W2946931105 hasAuthorship W2946931105A5001993231 @default.
• W2946931105 hasAuthorship W2946931105A5018065406 @default.
• W2946931105 hasAuthorship W2946931105A5021326700 @default.
• W2946931105 hasAuthorship W2946931105A5031990860 @default.
• W2946931105 hasAuthorship W2946931105A5044492989 @default.
• W2946931105 hasAuthorship W2946931105A5046420010 @default.
• W2946931105 hasAuthorship W2946931105A5061609589 @default.
• W2946931105 hasAuthorship W2946931105A5068436236 @default.
• W2946931105 hasAuthorship W2946931105A5085444689 @default.
• W2946931105 hasBestOaLocation W29469311051 @default.
• W2946931105 hasConcept C126322002 @default.
• W2946931105 hasConcept C127413603 @default.
• W2946931105 hasConcept C17744445 @default.

• next